Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma|Uterine Cancer|Cervical Cancer|Endometrial Cancer
Interventions: BIOLOGICAL: Vigil|DRUG: Durvalumab
Sponsor: Mary Crowley Medical Research Center
Collaborators: Gradalis, Inc.|AstraZeneca